Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs) : bench to bedside

Abstract: A major characteristic of cancer is dysregulated cell division, which results in aberrant growth of cells. Consequently, medicinal targets that prevent cell division would be useful in the fight against cancer. The primary regulator of proliferation is a complex consisting of cyclin and cyclin-dependent kinases (CDKs). The FDA has granted approval for CDK inhibitors (CDKIs) to treat metastatic hormone receptor-positive breast cancer. Specifically, CDK4/6 CDKIs block the enzyme activity of CDK4 and CDK6. Unfortunately, the majority of first-generation CDK inhibitors, also known as pan-CDK inhibitors because they target multiple CDKs, have not been authorized for clinical use owing to their serious side effects and lack of selection. In contrast to this, significant advancements have been created to permit the use of pan-CDK inhibitors in therapeutic settings. Notably, the toxicity and negative consequences of pan-CDK inhibitors have been lessened in recent years thanks to the emerge.... https://www.excli.de/index.php/excli/article/view/7076

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs) ; volume:23 ; year:2024 ; EXCLI journal ; 23 (2024)

Contributors, Places and Time

• Creator: Hassanzadeh, Ali ; Shomali, Navid ; Kamrani, Amin ; Soltani-Zangbar, Mohammad Sadegh ; Nasiri, Hadi ; Akbari, Morteza

Further information

• DOI: 10.17179/excli2024-7076
• URN: urn:nbn:de:101:1-2406210314522.949250938723
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 14.08.2025, 10:55 AM CEST